arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

PRECIGEN, INC.

PGEN
$4.17 ▼ -0.89 (-17.59%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
58 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Bearish
auto_awesome

Analytical Summary

PRECIGEN, INC. faces fundamental challenges with weakness in Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $1.5B
Dividend Yield —
Revenue Growth 6322.7%
Op. Margin 41.2% ↗
ROIC 16.5% ↗
FCF / Share $-0.05 ↗
Trailing P/E 69.5x
Price / Book 34.3x
FCF Yield —
Debt / Equity 2.15
info Valuation on last close. End-of-day price, Nov 5, 2026.

58-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$54.98M
↑ +6322.7% —
Net Income Profit after all expenses
$20.07M
↑ +353.1% —
Operating Margin Operating profit as % of sales
41.2%
↑ +259.8% —
FCF / Share Free cash flow per share
$-0.05
↑ +24.2% —
Long-Term Debt Long-term obligations
$93.88M
— +0.4% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Financial Health ↑
13
Cash Quality ↓
34

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 16 years · 58 quarters